LEQVIO®▼ (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.
LEQVIO® resources
Explore our growing repository of resources designed to provide useful information on LEQVIO® and other relevant topics for healthcare professionals treating eligible patients with ASCVD.
Patient’s guide to LEQVIO®
Patient’s guide to LEQVIO®
Please note that this material should only be shared with patients for whom the decision to prescribe LEQVIO® has already been made.
This downloadable PDF can be shared with your LEQVIO® patients to provide them with further information on their condition and useful information regarding taking LEQVIO®.
Please do not share this web page directly with patients; instead, please direct them to the patient portal.
Please get in touch with us to speak to one of our Novartis representative
ASCVD, atherosclerotic cardiovascular disease; ESC, European Society of Cardiology; HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; MOA, mechanism of action.
References
LEQVIO® Summary of Product Characteristics.
Wright RS, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Presented at ESC Congress 2023, Amsterdam, 25–28 August 2023. Oral presentation.
National Health Service. Summary of National Guidance for Lipid Management for Primary and Secondary Prevent of CVD. Available at: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v7.pdf [Accessed March 2025].
Ray KK, et al. N Engl J Med 2020;382(16):1507–1519.
UK | March 2025 | FA-11361470
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
